All Episodes
ToxChats© — 51 episodes
Next-Gen Toxicology: Inside the Organ Chip Revolution with Dr. Donald Ingber
Transitioning from Industry to Consulting, Independent vs. Firm Consultant
Human and Environmental Health Topic: Next Generation Risk Assessment
The Science of Mentorship: A Conversation with Richard DiMarchi
From RIF to Reboot: A Guide for Early to Mid-Career Toxicologists
Discussing the FDA's Announcement to Phase Out Animal Testing in Monoclonal Antibody Development
Specialty Tox Topic: In Vivo Dermal Drug Development
Specialty Tox Topic: In Vitro Dermal Drug Development
Occupational Toxicology and Product Quality: Navigating Impurities and Occupational Safety
The Past, Present, and Future of Safety Pharmacology
Career Path: Toxicologist in the Food Industry
Changing Approaches to Getting Drug Candidates into First-in-Human Clinical Trials: A Case Study
Career Path: Pharmaceutical Consultant in the Field of Toxicology
3D Printing Emissions and Potential Health Effects from a Consumer Perspective
Career Path: Pharmaceutical Consultant in the Field of Occupational, Environmental, and Quality Toxicology
Discussions on Identifying Seizures Liability in Nonclinical Studies
Alternative and Nontraditional Species Series: The Use of Transgenic and Disease Mouse Animal Models for Toxicology Studies
Identifying an Appropriate Sponsor to Support Your Growth and Success in the Workplace
Alternative and Nontraditional Species Series: Fertilized Egg Model as an Alternative Species for Safety Assessment Studies
Alternative and Nontraditional Species Series: Advantages and Challenges of Using Rabbits
Alternative and Nontraditional Species Series: Sheep as an Alternative Model for the Safety Evaluation of Medical Devices
Alternative and Nontraditional Species Series: Mini Pig–Alternatives to Traditional Nonrodent Models in Nonclinical Safety Testing
Medical Devices: Safety Evaluation and Becoming a Medical Device Toxicologist
Interviewing and Negotiation 101 for Toxicologist Roles in the Biopharmaceutical Industry
The History and Future of Oligonucleotide Drug Development
The Opioid Crisis: Misconceptions, History, and Interventions
Covid-19 Part 2: New Type of Antibody-Dependent Enhancement Associated with SARS-CoV-2 Virus: MIS-C, MIS-A, and MIS-N
Covid-19 Part 1: Antibody-dependent Enhancement of Disease
Artificial Intelligence (AI) Use in Toxicology
Overview of mRNA Vaccines
Tips for Taking the ABT Exam
Moving from Minion to Manager
Off the Beaten Path: The Nonclinical Development of Gene Therapy Products to Cure Monogenic Diseases
Digital Pathology
Expedited FDA Programs
Toxicology Salary Survey
Pediatric Drug Development
CAR/T: New Modalities Paving the Way for Cancer
History and Risk Assessment of Vaccines—Q&A
Scientific Communication: Distilling and Rehearsing to Reach Your Audience
AI and Big Data for Safety Testing
Shining a Light on the Science and Strategy of Phototoxicity Assessments
The Twists and Turns of GI Health and Medicine: An Interview with Dr. Alessio Fasano
The Scientific Approach to Address Uncommon Routes and Best Practices for Forming a Working Group
CRISPR Then and Now: An Interview with Dr. Jacob Corn, ACT 2015 Plenary Speaker
In Vitro and Alternative Models for Regulatory Submission
Regulation of E-Cigarettes
The Opioid Epidemic
Biomarkers
Microbiome
Oligonucleotide Therapeutics